Amarin Corporation PLC (AMRN) Receiving Somewhat Favorable News Coverage, Report Shows
Media coverage about Amarin Corporation PLC (NASDAQ:AMRN) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amarin Corporation PLC earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.2725373088255 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- ETFs with exposure to Amarin Corp. Plc : September 12, 2017 (finance.yahoo.com)
- Amarin Corporation plc (AMRN) Stocks Generate Strong EPS Growth Rate – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Analysts said to Buy Healthcare Stock: Amarin Corporation plc (AMRN) – Street Observer (press release) (streetobserver.com)
- Amarin Corporation plc (AMRN) Stock Price trades -4.67% off from 200- SMA – Voice Of Analysts (analystsbuzz.com)
- Amarin Corporation plc – Americ (NASDAQ:AMRN) Stock Closed -8.5% Below Its 50 Day Average – First News 24 (firstnewspaper24.com)
A number of equities analysts have issued reports on the stock. BidaskClub raised shares of Amarin Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 6th. Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. Jefferies Group LLC raised their price target on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, June 30th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.35.
Shares of Amarin Corporation PLC (NASDAQ:AMRN) opened at 3.16 on Tuesday. The company has a 50-day moving average of $3.38 and a 200 day moving average of $3.31. Amarin Corporation PLC has a one year low of $2.56 and a one year high of $4.47. The stock’s market cap is $855.70 million.
Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The business had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $40.35 million. During the same quarter in the previous year, the company posted ($0.07) EPS. The company’s revenue was up 37.0% compared to the same quarter last year. On average, equities analysts forecast that Amarin Corporation PLC will post ($0.21) earnings per share for the current fiscal year.
In other news, General Counsel Joseph T. Kennedy sold 307,911 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total value of $1,231,644.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.72% of the company’s stock.
Amarin Corporation PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.